CalciMedica (NASDAQ:CALC) Director Fred Middleton Buys 248,972 Shares of Stock

CalciMedica Inc. (NASDAQ:CALC) Director Fred Middleton acquired 248,972 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average price of $0.80 per share, with a total value of $199,177.60. Following the completion of the transaction, the director directly owned 1,063,272 shares in the company, valued at $850,617.60. This trade represents a 30.57% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CalciMedica Price Performance

CALC traded up $0.09 during trading on Monday, reaching $0.91. The company had a trading volume of 547,977 shares, compared to its average volume of 1,237,462. The company has a market cap of $14.36 million, a P/E ratio of -0.67 and a beta of 0.97. CalciMedica Inc. has a 12 month low of $0.46 and a 12 month high of $7.20. The business’s fifty day moving average price is $0.72 and its 200 day moving average price is $1.92.

Institutional Investors Weigh In On CalciMedica

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers lifted its position in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after buying an additional 9,045 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after acquiring an additional 18,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of CalciMedica in the fourth quarter valued at about $127,000. Envestnet Asset Management Inc. raised its holdings in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after acquiring an additional 34,386 shares in the last quarter. Finally, PVG Asset Management Corp acquired a new position in CalciMedica during the fourth quarter valued at approximately $302,000.

Analysts Set New Price Targets

Separately, Oppenheimer dropped their price target on CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.